Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Open accessAbstract
Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with toxicity. Methods. This study was conducted to assess the utility of measuring voriconazole blood levels with individualized dose adjustments. Results. A total of 181 measurements with high-pressure liquid chromatography were performed during 2388 treatment days in 52 patients. A large variability in voriconazole trough blood levels was observed, ranging from ⩽1 mg/L (the minimum inhibitory concentration at which, for most fungal pathogens, 90% of isolates are susceptible) in 25% of cases to >5.5 mg/L (a level possibly associated with toxicity) in 31% of cases. Lack of response to therapy was more frequent in patients with voriconazole levels ⩽1 mg/L (6 [46%] of 13 patients, including 5 patients with aspergillosis, 4 of whom were treated orally with a median dosage of 6 mg/kg per day) than in those with voriconazole levels >1 mg/L (15 [12%] of 39 patients; P=.02). Blood levels >1 mg/L were reached after increasing the voriconazole dosage, with complete resolution of infection in all 6 cases. Among 16 patients with voriconazole trough blood levels >5.5 mg/L, 5 patients (31%) presented with an encephalopathy, including 4 patients who were treated intravenously with a median voriconazole dosage of 8 mg/kg per day, whereas none of the patients with levels ⩽5.5 mg/L presented with neurological toxicity (P=.002). Comedication with omeprazole possibly contributed to voriconazole accumulation in 4 patients. In all cases, discontinuation of therapy resulted in prompt and complete neurological recovery. Conclusions. Voriconazole therapeutic drug monitoring improves the efficacy and safety of therapy in severely ill patients with invasive mycoses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment success in retrospective analyses has been associated with voriconazole serum trough concentrations of 1 to 2 mg/mL.
“Treatment success in these retrospective analyses has been associated with serum trough concentrations of 1 to 2 mg/mL.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304 · see citing works
Aşçıoğlu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Billé, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,315 · see citing works
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · see citing works
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · see citing works
Voriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 782 · see citing works
Walsh, T. J., RAAD, I. I., Patterson, T. F., Chandrasekar, P. H., Donowitz, G. R., Graybill, R. J., Greene, R. E., Hachem, R. Y., Hadley, S., Herbrecht, R., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508774 · Cited by 749 · see citing works
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., Dupont, B., Torre‐Cisneros, J., Just‐Nübling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 672 · see citing works
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521 · see citing works
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399 · see citing works
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391 · see citing works
Identification of the Cytochrome P450 Enzymes Involved in the N-Oxidation of Voriconazole
Hyland, R., Jones, B. C., & Smith, D. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.540 · Cited by 383 · see citing works
Walsh, T. J., Karlsson, M. O., Driscoll, T., Arguedas, A. G., Adamson, P. C., Sáez‐Llorens, X., Vora, A. J., Arrieta, A. C., Blumer, J. L., Lutsar, I., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2166-2172.2004 · Cited by 337 · see citing works
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R. E., Lewis, J. S., Martin, C. A., & Andes, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 311 · see citing works
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · see citing works
Tan, K., Brayshaw, N., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256 · see citing works
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · see citing works
Trifilio, S. M., Pennick, G. J., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., WILLIAMS, S. F., Winter, J. N., Tallman, M. S., et al. (2007) · Cancer · doi:10.1002/cncr.22568 · Cited by 198 · see citing works
Adverse Reactions to Voriconazole
Boyd, A. E., Modi, S., Howard, S. J., Moore, C. B., Keevil, B. G., & Denning, D. W. (2004) · Clinical Infectious Diseases · doi:10.1086/424662 · Cited by 182 · see citing works
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S. M., Ortiz, R., Pennick, G. J., Verma, A., Pi, J., Stosor, V., Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180 · see citing works
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients
Romero, A., Pogamp, P. L., Nilsson, L., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121911 · Cited by 171 · see citing works
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Imhof, A., Schaer, D. J., Schwarz, U., & Schanz, U. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11547 · Cited by 152 · see citing works
Pascual, A., Nieth, V., Calandra, T., Billé, J., Bolay, S., Decosterd, L. A., Buclin, T., Majcherczyk, P. A., Sanglard, D., & Marchetti, O. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00957-06 · Cited by 96 · see citing works
Self-citationTreatment options of invasive fungal infections in adults
Marchetti, O., Eggimann, P., Pittet, D., Glauser, M., & Calandra, T. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11392 · Cited by 89 · see citing works
Self-citationPotoski, B. A., & Brown, J. E. (2002) · Clinical Infectious Diseases · doi:10.1086/343746 · Cited by 87 · see citing works
Safety of Voriconazole and Dose Individualization
Lutsar, I., Hodges, M. R., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2003) · Clinical Infectious Diseases · doi:10.1086/374248 · Cited by 75 · see citing works
Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis
Sugar, A. M., & Liu, X. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.601-604.2001 · Cited by 73 · see citing works
Mallié, M., Bastide, J.-M., Blancard, A., Bonnin, A., Bretagne, S., Cambon, M., Chandenier, J., Chauveau, V., Couprie, B., Datry, A., et al. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.11.010 · Cited by 65 · see citing works
den Hollander, J. G. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl108 · Cited by 60 · see citing works
Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods
Linares, M. J., Charriel, G., Solís, F., Rodríguez, F., Ibarra, A., & Casal, M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.250-253.2005 · Cited by 55 · see citing works
Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis
Weiler, S., Zoller, H., Graziadei, I. W., Vogel, W., Bellmann‐Weiler, R., Joannidis, M., & Bellmann, R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-07 · Cited by 50 · see citing works
Interaction between voriconazole and tacrolimus in a kidney-transplanted patient
Tintillier, M., Kirch, L., Goffin, E. J., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh593 · Cited by 41 · see citing works
Almyroudis, N. G., Kontoyiannis, D. P., Sepkowitz, K. A., dePauw, B. E., Walsh, T. J., & Segal, B. H. (2006) · Clinical Infectious Diseases · doi:10.1086/508455 · Cited by 35 · see citing works
Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients
Mohammédi, I., Piens, M. A., Padoin, C., & Robert, D. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-1325-7 · Cited by 30 · see citing works
How Does a Patient Maximally Benefit from Anti-infective Chemotherapy?
Drusano, G. L. (2004) · Clinical Infectious Diseases · doi:10.1086/424673 · Cited by 17 · see citing works
Schön, C., Bullinger, L., Rücker, F. G., et al. (2006) · Blood · doi:10.1182/blood.v108.11.806.806 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [15]15. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 ; 50:1570-2.
- [34]34. Trifilio S, Singhal S, Winter J, et al. ASH Annual Meeting 2006, Orlando, FL [abstract 2849]. Blood 2006 ; 108:806a-807a.
Cited by
Sorted by citations
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463 · see citing works
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Self-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works
Self-citationCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · see citing works
Self-citationThe biology and chemistry of antifungal agents: A review
Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664 · see citing works
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490 · see citing works
Self-citationESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386 · see citing works
Self-citationHope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360 · see citing works
Self-citationNett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
Bench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217 · see citing works
Self-citationTherapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
Smith, J., & Andes, D. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318167d0e0 · Cited by 156 · see citing works
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134 · see citing works
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129 · see citing works
Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives
Alastruey-Izquierdo, A., Cadranel, J., Flick, H., Godet, C., Hennequin, C., Hoenigl, M., Kosmidis, C., Lange, C., Munteanu, O., Page, I., et al. (2018) · Respiration · doi:10.1159/000489474 · Cited by 126 · see citing works
Espinel-Ingroff, A. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70004-x · Cited by 105 · see citing works
New generation azole antifungals in clinical investigation
Girmenia, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903176407 · Cited by 107 · see citing works
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100 · see citing works
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63 · see citing works
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62 · see citing works
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · see citing works
Siopi, M., Siafakas, N., Vourli, S., Mouton, J. W., Zerva, L., & Meletiadis, J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw276 · Cited by 23 · see citing works
Siopi, M., Siafakas, N., Vourli, S., Zerva, L., & Meletiadis, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05035-14 · Cited by 22 · see citing works
- Authors
- Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Marchetti, O.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-15
- Volume
- 46
- Issue
- 2
- Pages
- 201-211
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2162857158
- Cited by
- 887
- References
- 36
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 26 · 2023: 34 · 2022: 30 · 2021: 37 · 2020: 45 · 2019: 42 · 2018: 36 · 2017: 42 · 2016: 63 · 2015: 61 · 2014: 58 · 2013: 57 · 2012: 66
- FWCI
- 35.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- voriconazole, therapeutic drug monitoring, invasive fungal infections, aspergillosis, candidiasis, pharmacokinetics, dose adjustment, CYP2C19 polymorphism, encephalopathy, antifungal toxicity, treatment efficacy
- MeSH terms
- Adult, Aged, Antifungal Agents, Aspergillosis, Candidiasis, Chromatography, High Pressure Liquid, Female, Humans, Male, Middle Aged, Mycoses, Pyrimidines, Retrospective Studies, Triazoles, Drug Monitoring, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
